Suchergebnisse - "Fabi, A"

PubPharm (154)

1

Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer : An Italian consensus paper and critical review" [Cancer Treatm. Rev. 114 (2023) 102511

enthalten in: Cancer treatment reviews | 2023

von Miglietta, F. | Fabi, A. | Generali, D. | +14

ErratumFor: Cancer Treat Rev. 2023 Mar;114:102511. - PMID 36638600

2

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer : An Italian consensus paper and critical review

enthalten in: Cancer treatment reviews | 2023

von Miglietta, F. | Fabi, A. | Generali, D. | +14

ErratumIn: Cancer Treat Rev. 2023 Jun;117:102570. - PMID 37150120

3

Isquemia crÃ³nica que amenaza las extremidades inferiores: diagnÃ³stico y tratamiento. RevisiÃ³n bibliogrÃ¡fica enfocada al primer nivel de atenciÃ³n mÃ©dica

in: Revista Mexicana de Angiología | 2023

von FabiÃ¡n D. Arias-RodrÃguez | Pamela J. ProaÃ±o-ProaÃ±o | Steven L. Posligua-Cevallos | +6

4

Corrigendum to "Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer : An Italian consensus paper and critical review" [Cancer Treat. Rev. 114 (2023) 102511

enthalten in: Cancer treatment reviews | 2023

von Miglietta, F. | Fabi, A. | Generali, D. | +14

ErratumFor: Cancer Treat Rev. 2023 Mar;114:102511. - PMID 36638600

5

Adherence to endocrine therapy in women with breast cancer : development and preliminary validation of the A-BET questionnaire

enthalten in: La Clinica terapeutica | 2022

von Gambalunga, F. | Iacorossi, L. | Terrenato, I. | +5

6

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer : an Italian multicenter observational study

enthalten in: ESMO open | 2021

von Schettini, F. | Conte, B. | Buono, G. | +25

7

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab : a multicenter, phase II, single arm trial (GIM11-BERGI)

enthalten in: ESMO open | 2021

von De Angelis, C. | Bruzzese, D. | Bernardo, A. | +16

ErratumIn: ESMO Open. 2021 Apr;6(2):100097. - PMID 33926709

8

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab : a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054

enthalten in: ESMO open | 2021

von De Angelis, C. | Bruzzese, D. | Bernardo, A. | +18

ErratumFor: ESMO Open. 2021 Feb 15;6(2):100054. - PMID 33601296

9

Cancer-related fatigue : ESMO Clinical Practice Guidelines for diagnosis and treatment

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von Fabi, A. | Bhargava, R. | Fatigoni, S. | +7

10

Influence of Olfactory and Visual Sensory Stimuli in the Perfume-Purchase Decision

in: International Review of Management and Marketing | 2020

von FabiÃ¡n Cuesta | Gabriela Paida | Irene Buele

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]